Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Myocardial no-reflow in humans
In a variable proportion of patients presenting with ST-segment elevation myocardial
infarction, ranging from 5% to 50%, primary percutaneous coronary intervention achieves …
infarction, ranging from 5% to 50%, primary percutaneous coronary intervention achieves …
Platelet receptors and signaling in the dynamics of thrombus formation
Hemostasis and pathological thrombus formation are dynamic processes that require a co-
ordinated series of events involving platelet membrane receptors, bidirectional intracellular …
ordinated series of events involving platelet membrane receptors, bidirectional intracellular …
Coronary no reflow
BG Schwartz, RA Kloner - Journal of molecular and cellular cardiology, 2012 - Elsevier
The no-reflow phenomenon has been studied extensively in the basic science laboratory
and has entered the clinical arena. No-reflow, which develops largely within the first 2h of …
and has entered the clinical arena. No-reflow, which develops largely within the first 2h of …
Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention
Aims Microparticles (MP) are cell-derived fragments known to be increased in the blood of
patients with acute coronary syndromes. We aimed to assess, in ST elevation myocardial …
patients with acute coronary syndromes. We aimed to assess, in ST elevation myocardial …
Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure
K Barrett Mueller, SB Bender, K Hong, Y Yang… - …, 2015 - ahajournals.org
Arteriolar vasoreactivity tightly regulates tissue-specific blood flow and contributes to
systemic blood pressure (BP) but becomes dysfunctional in the setting of cardiovascular …
systemic blood pressure (BP) but becomes dysfunctional in the setting of cardiovascular …
Neuropeptide‐Y Levels in ST‐Segment–Elevation Myocardial Infarction: Relationship With Coronary Microvascular Function, Heart Failure, and Mortality
T Gibbs, N Tapoulal, M Shanmuganathan… - Journal of the …, 2022 - ahajournals.org
Background The sympathetic cotransmitter, neuropeptide Y (NPY), is released into the
coronary sinus during ST‐segment–elevation myocardial infarction and can constrict the …
coronary sinus during ST‐segment–elevation myocardial infarction and can constrict the …
Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides
High levels of sympathetic drive in several cardiovascular diseases including
postmyocardial infarction, chronic congestive heart failure and hypertension are reinforced …
postmyocardial infarction, chronic congestive heart failure and hypertension are reinforced …
Pathophysiology of the no-reflow phenomenon
CJM Vrints - Acute Cardiac Care, 2009 - Taylor & Francis
The no-reflow phenomenon occurs in about one third of the patients treated with primary PCI
for acute ST segment elevation myocardial infarction. Our understanding of its …
for acute ST segment elevation myocardial infarction. Our understanding of its …
Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial …
Objectives The co-transmitter neuropeptide Y (NPY) is released during high levels of
sympathetic stimulation and is a potent vasoconstrictor. We defined the release profile of …
sympathetic stimulation and is a potent vasoconstrictor. We defined the release profile of …
Thromboxane A2 Receptor Antagonism by Flavonoids: Structure−Activity Relationships
Thromboxane A2 (TxA2) is a strong platelet agonist involved in the pathogenesis of
thrombotic diseases that elicits platelet aggregation and vasoconstriction through the …
thrombotic diseases that elicits platelet aggregation and vasoconstriction through the …